Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Lynch Syndrome: early-phase trial registry

9 of 22 indexed Lynch Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 9 currently recruiting · #756 of 28,707 conditions by registered trial count

Lynch Syndrome: 22 US clinical trials tracked, 9 recruiting.

Lynch Syndrome is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition lynch-syndrome

OPEN 9 | RECR 41% | LATE 2 | EARLY 4 | RANK #756 | SPON 4

Nearest open-share peer: Brain Injuries, Traumatic (41% recruiting · 22 trials)

Advanced Melanoma63.6%Lynch Syndrome (this)41%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Lynch Syndrome

Lynch Syndrome lists 9 open slots (41% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lynch Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lynch Syndrome recruits in line with its size-band peers.

    9 of 22 indexed trials (40.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lynch Syndrome research.

    M.D. Anderson Cancer Center accounts for 4 of 22 trials (18.2%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lynch Syndrome enrolment sits around 337 participants.

    Median target enrolment is 337 among the 22 trials that report a genuine target (sentinel values excluded). 6 of those (27.3%) plan for fewer than 100 participants.

  4. Lynch Syndrome splits between interventional and observational designs.

    14 interventional and 8 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 32

Open and recent trials

22 total, page 1 of 1

RECRUITING NA 27,500 participants

Identifying and Caring for Individuals With Inherited Cancer Syndrome

OHSU Knight Cancer Institute

NCT04494945

RECRUITING Phase 3 9,000 participants

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins University

NCT02000089

RECRUITING 5,000 participants

Lynch Syndrome Integrative Epidemiology and Genetics

University of Colorado, Denver

NCT06582914

RECRUITING 750 participants

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

Mayo Clinic

NCT05410977

RECRUITING 400 participants

Prostate Cancer Genetic Risk Evaluation and Screening Study

Massachusetts General Hospital

NCT05129605

RECRUITING 300 participants

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

San Raffaele University

NCT06708429

RECRUITING Phase 2 40 participants

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

M.D. Anderson Cancer Center

NCT05411718

RECRUITING NA 30 participants

A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule

Massachusetts General Hospital

NCT07219537

RECRUITING NA 25 participants

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

Jessica D. St. Laurent, MD

NCT07220239

ACTIVE NOT RECRUITING 1,530 participants

Multi-Organ Screening Recommendations in Patients With Lynch Syndrome

Memorial Sloan Kettering Cancer Center

NCT00582296

ACTIVE NOT RECRUITING NA 932 participants

Scalable Communication Modalities for Returning Genetic Research Results

Boston University

NCT04407611

ACTIVE NOT RECRUITING Phase 3 712 participants

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

NCT02912559

ACTIVE NOT RECRUITING NA 384 participants

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

M.D. Anderson Cancer Center

NCT04125914

ACTIVE NOT RECRUITING NA 337 participants

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

M.D. Anderson Cancer Center

NCT02194387

ACTIVE NOT RECRUITING 317 participants

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

H. Lee Moffitt Cancer Center and Research Institute

NCT05692596

ACTIVE NOT RECRUITING NA 205 participants

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

M.D. Anderson Cancer Center

NCT05677048

ACTIVE NOT RECRUITING Phase 2 186 participants

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

National Cancer Institute (NCI)

NCT05419011

ACTIVE NOT RECRUITING 100 participants

Pancreatic Cancer Early Detection Program

White Plains Hospital

NCT02206360

ACTIVE NOT RECRUITING 77 participants

Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes

Memorial Sloan Kettering Cancer Center

NCT02371135

ACTIVE NOT RECRUITING Phase 1 71 participants

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

NCT02359565

ACTIVE NOT RECRUITING Phase 1 45 participants

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

National Cancer Institute (NCI)

NCT05078866

COMPLETED NA 703 participants

Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants

Geisinger Clinic

NCT04131062

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on Lynch Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Biospecimen Collection Procedure
6 trials
Internet-Based Intervention Other
2 trials
Electronic Consent (iPad) Behavioral
1 trials
questionnaires, telephone interview and optional blood drawn Behavioral
1 trials
questionnaires, telephone interview, optional blood drawn Behavioral
1 trials
MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP Biological
1 trials
Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP Biological
1 trials
Genetic counselor follow-up Behavioral
1 trials

US sites by state

Facility locations filed on Lynch Syndrome trials. A trial with sites in several states counts in each.

Texas 7 trials
Massachusetts 7 trials
Pennsylvania 6 trials
California 6 trials
New York 5 trials
Colorado 4 trials
Ohio 3 trials
Illinois 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lynch Syndrome page

22 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lynch Syndrome condition card totals 22 registered trials; most-linked intervention Biospecimen Collection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.